While GLP-1 receptor agonists and bariatric surgery offer significant metabolic benefits, experts caution that rapid weight ...

A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

People taking semaglutide or liraglutide reduced their alcohol consumption by two-thirds within four months, according to results recently published in the journal Diabetes, Obesity and Metabolism.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...